Drug notes:
Additional undisclosed programs RD ALS, rare pediatric neurological disorders, epilepsy, fragile X syndrome
About:
NeuCyte is focused on advancing the field of neuroscience through the development of innovative drug discovery and development tools. Their primary focus is on CNS drug discovery. NeuCyte’s proprietary SynFire technology offers highly differentiated and mature induced neurons that closely resemble real human neurobiology. These iPSC-derived induced neurons (SynFire iNs) are ideal for in vitro studies of neural diseases, drug screening, and mechanism-of-action investigations. They also have a service division. NeuCyte provides comprehensive services to support the early stages of drug development, including lead compound optimization and nonclinical safety assessment. NeuCyte is developing a number of drug discovery programs in a variety of neurological disorders, including Alzheimer’s, epilepsy and more.